<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292419</url>
  </required_header>
  <id_info>
    <org_study_id>43306</org_study_id>
    <nct_id>NCT03292419</nct_id>
  </id_info>
  <brief_title>Topography-guided LASIK Surgery</brief_title>
  <official_title>A Prospective Evaluation of Topography-guided LASIK Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are analyzing outcomes of topography-guided LASIK surgery in participants
      with myopia and myopic astigmatism
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are analyzing outcomes of topography-guided LASIK surgery in participants
      with myopia and myopic astigmatism. The investigators will be monitoring changes in anterior
      segment optical coherence tomography epithelial thickness maps. The investigators will
      compare preoperative maps to postoperative maps at one, three, six and twelve months. In
      addition, the investigators will measure changes in epithelial maps from postoperative month
      through twelve months to help understand what is happening to the corneal epithelium to try
      to explain why UDVA and CDVA improves over time
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Topography guided</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>N0ne</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Epithelial thickness maps</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in anterior segment optical coherence tomography epithelial thickness maps.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Corrected distance visual acuity (CDVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Uncorrected distance visual acuity (UDVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Vision</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported outcomes questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictability</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of eyes within +/-0.25, 0.50 and 1.00 diopter of the intended correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>5 and 25% ETDRS contrast acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual astigmatism levels after surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Vector analysis of astigmatic outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in refraction over time</measure>
    <time_frame>12 months</time_frame>
    <description>Change in spherical equivalent over time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Topography guided LASI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Topography-guided LASIK</intervention_name>
    <description>LASIK surgery</description>
    <arm_group_label>Topography guided LASI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects age 18 and older with healthy eyes. Nearsightedness between -0.50 diopters
             and -8.00 diopters.

          -  Subjects with up to 3.00 diopters of astigmatism.

          -  Subjects with a spherical equivalent of up to -9.00 diopters.

        Exclusion Criteria:

          -  Subjects under the age of 18.

          -  Subjects with excessively thin corneas.

          -  Subjects with topographic evidence of keratoconus.

          -  Subjects with ectatic eye disorders.

          -  Subjects with autoimmune diseases.

          -  Subjects who are pregnant or nursing.

          -  Subjects with more than 3.00 diopters of astigmatism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

